Protara Therapeutics, Inc.
TARA
$3.40
-$0.12-3.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -44.60M | -42.05M | -40.69M | -42.47M | -40.42M |
| Total Depreciation and Amortization | 332.00K | 357.00K | 352.00K | 347.00K | 341.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.45M | 5.21M | 5.70M | 6.22M | 6.66M |
| Change in Net Operating Assets | 4.01M | 1.29M | 1.31M | 855.00K | -4.14M |
| Cash from Operations | -35.81M | -35.20M | -33.33M | -35.05M | -37.56M |
| Capital Expenditure | -63.00K | -63.00K | -92.00K | -39.00K | -45.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 19.22M | 11.24M | 47.03M | 66.39M | 53.15M |
| Cash from Investing | 19.16M | 11.17M | 46.94M | 66.35M | 53.11M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 149.03M | 45.13M | 135.00K | -- | -- |
| Repurchase of Common Stock | -83.00K | -83.00K | -110.00K | -103.00K | -91.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.09M | -3.03M | 41.96M | -- | -- |
| Cash from Financing | 139.87M | 42.02M | 41.99M | -103.00K | -91.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 123.21M | 17.99M | 55.60M | 31.20M | 15.46M |